Nu-Seals Cardio (Acetylsalicylic Acid)

Nu‑Seals Cardio is an antiplatelet medication that acts on platelet aggregation pathways to lower thrombotic risk.

• Acute coronary syndrome: helps prevent further myocardial injury and recurrent ischemic events.
• Post‑myocardial infarction: reduces the risk of subsequent heart attacks and cardiovascular death.
• Stroke prevention in patients with a history of ischemic stroke or transient ischemic attack: lowers recurrence risk.
• Peripheral arterial disease: diminishes the chance of limb‑related ischemic complications.
• Primary prevention in high‑risk adults: modestly reduces first‑time cardiovascular events when risk outweighs bleeding concerns.

• Acetylsalicylic acid irreversibly acetylates the cyclooxygenase‑1 (COX‑1) enzyme in platelets, blocking the conversion of arachidonic acid to thromboxane A2, a potent promoter of platelet aggregation. This inhibition persists for the lifespan of the platelet (7–10 days), providing sustained antiplatelet activity while sparing COX‑2 mediated prostacyclin production in vascular endothelium.

Adverse reactions to Nu‑Seals Cardio vary from mild to severe and should be monitored during therapy.

Common Side Effects

• Gastrointestinal discomfort or dyspepsia.
• Minor bruising or easy bleeding from cuts.
• Nausea or mild stomach upset.
• Heartburn or acid reflux symptoms.
• Headache.

Serious or Rare Side Effects

• Gastrointestinal ulceration or serious bleeding.
• Intracranial hemorrhage.
• Severe allergic reactions such as anaphylaxis.
• Renal impairment or acute kidney injury.
• Reye syndrome in children and adolescents.
• Thrombocytopenia or other blood dyscrasias.

When prescribing Nu‑Seals Cardio, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

• Bleeding risk assessment: review history of ulcers, anticoagulant use, or coagulopathy.
• Gastrointestinal protection: consider a proton‑pump inhibitor in patients with prior ulcer disease.
• Renal function monitoring: adjust use in patients with chronic kidney disease.
• Asthma caution: avoid in patients with aspirin‑exacerbated respiratory disease.
• Pregnancy and lactation: use only if clearly indicated and benefits outweigh risks.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

Nu‑Seals Cardio can alter the safety or efficacy of several concomitant medicines. Proper review of a patient’s medication list is essential.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk.
• Selective COX‑2 inhibitors (e.g., celecoxib): additive gastrointestinal toxicity.
• Corticosteroids: heightened risk of gastrointestinal ulceration.

Moderate Interactions (Monitor Closely)

• SSRIs or SNRIs (e.g., sertraline, venlafaxine): may modestly increase bleeding.
• ACE inhibitors or ARBs: can affect renal perfusion when combined with NSAID effect.
• Diuretics: potential for reduced renal clearance of aspirin.